Trial Profile

LSD Therapy for Persons Suffering From Major Depression: A Randomised, Double-blind, Active-placebo Controlled Phase II Study

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 04 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lysergide (Primary)
Indications Major depressive disorder
Focus Therapeutic Use

Most Recent Events

12 Jan 2026 According to Definium Therapeutics media release, MindMed is now called as Definium Therapeutics.
14 Apr 2023 Primary endpoint (Change in depressive symptomatology assessed by questionnaire compared with active placebo) has been met, according to a Mindmed media release.
14 Apr 2023 According to Mindmed media release, Prof. Matthias Liechti, is the co-primary investigator of the trial.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com